Age-based (<65 vs ≥65 years) incidence of infections and serious infections with tofacitinib versus biological DMARDs in rheumatoid arthritis clinical trials and the US Corrona RA registry

Ann Rheum Dis. 2021 Jan;80(1):134-136. doi: 10.1136/annrheumdis-2020-218992. Epub 2020 Oct 12.
No abstract available

Keywords: adalimumab; antirheumatic agents; arthritis; biological therapy; rheumatoid; tumor necrosis factor inhibitors.

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adalimumab / therapeutic use*
  • Age Factors
  • Aged
  • Antirheumatic Agents / therapeutic use*
  • Arthritis, Rheumatoid / drug therapy*
  • Biological Products / therapeutic use
  • Female
  • Humans
  • Incidence
  • Infections / epidemiology*
  • Janus Kinase Inhibitors / therapeutic use*
  • Male
  • Middle Aged
  • Piperidines / therapeutic use*
  • Proportional Hazards Models
  • Pyrimidines / therapeutic use*
  • Registries*
  • Risk Factors
  • United States / epidemiology

Substances

  • Antirheumatic Agents
  • Biological Products
  • Janus Kinase Inhibitors
  • Piperidines
  • Pyrimidines
  • tofacitinib
  • Adalimumab